Racial and Geographic Differences in Endometrial Cancer Death.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-09-28 DOI:10.1159/000541683

Jia Yi Tan, Yong Hao Yeo, Jia Yean Thong, Sabera Saleh, Kelly Mbenga, Gunwant Guron, Hamid S Shaaban

{"title":"Racial and Geographic Differences in Endometrial Cancer Death.","authors":"Jia Yi Tan, Yong Hao Yeo, Jia Yean Thong, Sabera Saleh, Kelly Mbenga, Gunwant Guron, Hamid S Shaaban","doi":"10.1159/000541683","DOIUrl":null,"url":null,"abstract":"Introduction: In the USA, endometrial cancer incidence rose by 4.5% annually from 1999 to 2015, reaching 18 per 100,000 women, with a disproportionate impact on African American women. Despite advancements in endometrial cancer research, racial disparities in mortality rates persist. Our retrospective cohort study aimed to investigate the mortality trends and disparities among patients with endometrial cancer in the USA.Methods: Patients with endometrial cancer mortality from 1999 to 2020 were analyzed from the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER). Age-adjusted mortality rates (AAMRs) per 100,000 individuals were compared across different races and geographical regions.Results: From 1999 to 2020, endometrial cancer accounted for 90,145 deaths in the USA. Overall, the AAMRs of endometrial cancer increased significantly from 2.50 (95% CI, 2.41-2.58) in 1999 to 3.94 (95% CI, 3.85-4.04) per 100,000 individuals in 2020, with an AAPC of +2.23 (95% CI, 1.39-3.07). The highest AAMR was observed among African Americans (2.69 [95% CI, 2.65-2.74]), followed by whites (1.44 [95% CI, 1.43-1.45]), Hispanics (1.16 [95% CI, 1.13-1.20]), Asians (1.00 [95% CI, 0.96-1.04]), and American Indians (0.99 [95% CI, 0.88-1.10]). The highest AAMR from endometrial cancer was recorded in the Northeast region (1.73 [95% CI, 1.71-1.76]).Conclusion: There was an increasing trend of mortality rates from endometrial cancer in the last 2 decades, which disproportionately affected African Americans. Targeted interventions are warranted to address the mortality disparities among patients with endometrial cancer.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-5"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541683","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In the USA, endometrial cancer incidence rose by 4.5% annually from 1999 to 2015, reaching 18 per 100,000 women, with a disproportionate impact on African American women. Despite advancements in endometrial cancer research, racial disparities in mortality rates persist. Our retrospective cohort study aimed to investigate the mortality trends and disparities among patients with endometrial cancer in the USA.

Methods: Patients with endometrial cancer mortality from 1999 to 2020 were analyzed from the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER). Age-adjusted mortality rates (AAMRs) per 100,000 individuals were compared across different races and geographical regions.

Results: From 1999 to 2020, endometrial cancer accounted for 90,145 deaths in the USA. Overall, the AAMRs of endometrial cancer increased significantly from 2.50 (95% CI, 2.41-2.58) in 1999 to 3.94 (95% CI, 3.85-4.04) per 100,000 individuals in 2020, with an AAPC of +2.23 (95% CI, 1.39-3.07). The highest AAMR was observed among African Americans (2.69 [95% CI, 2.65-2.74]), followed by whites (1.44 [95% CI, 1.43-1.45]), Hispanics (1.16 [95% CI, 1.13-1.20]), Asians (1.00 [95% CI, 0.96-1.04]), and American Indians (0.99 [95% CI, 0.88-1.10]). The highest AAMR from endometrial cancer was recorded in the Northeast region (1.73 [95% CI, 1.71-1.76]).

Conclusion: There was an increasing trend of mortality rates from endometrial cancer in the last 2 decades, which disproportionately affected African Americans. Targeted interventions are warranted to address the mortality disparities among patients with endometrial cancer.

查看原文本刊更多论文

子宫内膜癌死亡的种族和地域差异。

导言在美国，子宫内膜癌的发病率在 1999-2015 年间每年上升 4.5%，达到每 10 万名妇女中有 18 人患子宫内膜癌，对黑人妇女的影响尤为严重。尽管子宫内膜癌研究取得了进展，但死亡率的种族差异依然存在。我们的回顾性队列研究旨在调查美国子宫内膜癌患者的死亡率趋势和差异。方法我们从美国疾病控制和预防中心的广泛流行病学研究在线数据（CDC WONDER）中分析了 1999 年至 2020 年期间子宫内膜癌患者的死亡率。比较了不同种族和地理区域每 10 万人的年龄调整死亡率 (AAMR)。结果从 1999 年到 2020 年，美国有 90,145 人死于子宫内膜癌。总体而言，子宫内膜癌的平均死亡率从 1999 年的每 10 万人 2.50 例（95% CI，2.41-2.58 例）大幅上升至 2020 年的 3.94 例（95% CI，3.85-4.04 例），AAPC 为 +2.23 例（95% CI，1.39-3.07 例）。非裔美国人的 AAMR 最高（2.69 [95% CI, 2.65-2.74]），其次是白人（1.44 [95% CI, 1.43-1.45]）、西班牙裔（1.16 [95% CI, 1.13-1.20]）、亚裔（1.00 [95% CI, 0.96-1.04]）和美洲印第安人（0.99 [95% CI, 0.88-1.10]）。东北部地区的子宫内膜癌死亡率最高（1.73 [95% CI, 1.71-1.76]）。结论在过去二十年中，子宫内膜癌的死亡率呈上升趋势，非裔美国人受到的影响尤为严重。有必要采取有针对性的干预措施来解决子宫内膜癌患者的死亡率差异问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.